IPSEN (OTCMKTS:IPSEY) Shares Gap Up – Here’s Why

IPSEN (OTCMKTS:IPSEY) shares gapped up before the market opened on Thursday . The stock had previously closed at $34.35, but opened at $36.80. IPSEN shares last traded at $36.80, with a volume of 580 shares changing hands.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on IPSEY. BNP Paribas lowered IPSEN to an “underperform” rating in a research report on Wednesday, November 26th. UBS Group downgraded IPSEN to a “neutral” rating in a research note on Thursday. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of IPSEN in a report on Monday, November 3rd. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold”.

IPSEN Stock Up 7.1%

The stock has a fifty day simple moving average of $35.89 and a two-hundred day simple moving average of $33.78.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).